How can pharma engage with key stakeholders on NHS service transformation?
August 17, 2018 |
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change
Introduction
There is a real drive for change within the NHS to ensure its sustainability in the long-term. However, discussions and decisions about transformational change mostly take place within the highest echelons of local NHS organisations.
When transformation teams do engage with staff from other parts of the service, it will generally be with small groups of clinical leaders; hence many ‘jobbing’ clinicians are left in the dark about change until it occurs.
However, NHS England’s ‘Planning, assuring and delivering service change for patients’, which provides a good practice guide for commissioners on the NHS England assurance process for major service changes and reconfiguration, states that clinical engagement and approval, and strong clinical evidence are key.
Assurance for NHS management within this paper means: is there documented evidence that the transformation process has looked at clinical best practice and engaged relevant clinical stakeholders? If not, the clinicians have a route to challenge the proposed changes.
Elements of the guide can be applied to lower levels of change, such as the introduction of new drugs to improve care pathways. This provides a powerful opportunity for pharma to activate clinicians to take a lead in service change and engage with other key stakeholders. It can also help pharma ensure that it fully understands the tests and assurance checks that should be applied to new drugs and services.
Getting the message across to clinicians
Pharma should keep clinicians abreast of transformational change that is happening in relevant disease areas and make sure its customers are consulted on it. By ensuring proposals are in line with the NHS England guidance and gathering as much clinical, and ideally real world, evidence as possible about the benefits of a new drug or service within the whole pathway, pharma can then demonstrate how it could add value to the transformation process.
Clinicians are very disease orientated, so for them the direct impact of a drug on patients, such as its ability to reduce side effects, is the overriding priority. However, commissioners are service focussed and such benefits are unlikely to be sufficient to convince commissioners to invest in a product since they are under pressure to deliver on much wider priorities, such as reducing the burden on A&E and on hospitals generally.
Pharma can help this discussion by supporting clinicians in reframing clinical benefits to highlight wider service benefits within the whole patient pathway, even outside a specific disease area. For, example, they could show the current cost and workforce implications of patients who do not tolerate current treatments and potentially need appointments and reviews, versus the cost of new treatments with better efficacy or side effect profiles.
NHS RightCare provides examples of this with its long-term condition scenarios, such as ‘Susan’s Story: Osteoporosis’, where costs are shown to be reduced by a factor of 10 if Susan is treated within an optimal care pathway. https://www.england.nhs.uk/rightcare/products/ltc/
Engaging with other key stakeholders
Having the right evidence base and framing the right messages in the right way to the right clinicians is a key step. However, pharma also needs to engage with other key stakeholders involved in transformational change and ensure that its value proposition is tailored according to local budgets and priorities as well as national ones.
This should involve developing messaging for the most senior NHS executives who are potentially focussing on four to five priorities, such as reducing pressure on A&E, the frail and elderly, or chaotic families. Industry should also refine its proposition for transformation leads, medicines management staff and other key opinion leaders (KOLs), who may have different drivers and priorities.
It should also be noted that in the 14 areas, which are early movers from STP to ICS/ICPPs (Integrated Care Provider Partnerships), former low-mid ranking CCG commissioners and project managers are transferring across to these new care models. They are taking up roles such as service improvement manager within the ICPPs; hence they are prime pharma targets as they are now working very closely with clinical teams.
Facilitating engagement between key stakeholders
There is also a role for pharma to play in assisting transformation leads within the Integrated Care System, or STP, to engage more widely within the NHS, particularly clinicians, when planning and implementing service change.
Networking between transformation leads, commissioners, service development managers, clinicians and patient representatives is vital and, if it is done well, it speeds up conversations, enables shortcuts, and helps change to happen faster and be shared more widely.
This is a key area where pharma can step in and get its customers, e.g. consultants and GPs, together to help them understand NHS transformation. Pharma could also offer to help transformation leads bring relevant stakeholders, such as clinicians and multi-service providers, together to better understand change and manage pathways.
Conclusion
There is an opportunity for pharma to activate clinicians within service change by making them aware of what is happening in their area and ensuring they understand the benefits of a new drug or service from both their own and a wider commissioning/transformation perspective.
Pharma can also take a lead in facilitating discussions between clinicians, transformation leads, medicines management staff and other key stakeholders/opinion leaders to help them better understand each other’s needs and priorities, and to ensure that proposals really will deliver the greatest possible value to the NHS.
Steve How, Paul Midgley and Oli Hudson are all part of Wilmington Healthcare’s consulting team. For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
A new vision for tackling key illnesses
Steve How and Oli Hudson, of Wilmington Healthcare, explore the NHS Long-term Plan’s strategy for delivering more preventative, joined-up services for major health conditions
Spotlight on innovation at life sciences forum
Paul Midgley, of Wilmington Healthcare, takes a look at the forthcoming HSJ Life Sciences Forum, where the NHS and industry will unite to discuss challenges and explore innovative solutions
GPs will play a pivotal role in integrated care
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explain how the new GP contract will shape local joined-up systems
What role for pharma in helping to deliver integrated care?
Steve How and Paul Midgley, of Wilmington Healthcare, explore how pharma can support local health economies in providing joined-up, holistic services
Winners of the HSJ Partnership Awards 2019 unveiled
The winners of the HSJ Partnership Awards 2019 were announced on 20 March at a prestigious black-tie awards ceremony at Park Plaza, Westminster.
Putting disease prevention on a par with cure
Steve How and Paul Midgley, of the Wilmington Healthcare Consulting Team, explore how the NHS is taking an increasingly holistic approach to care
What does the new NHS plan mean for pharma?
Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of the NHS Long-term Plan
HSJ Partnership Awards 2019 shortlist announced
The finalists for the HSJ Partnership Awards have been announced today ahead of a prestigious black-tie dinner awards ceremony at Park Plaza, Westminster Bridge on 20 March 2019.
Healthcare excellence celebrated at 2018 HSJ Awards
Thousands of healthcare professionals were in attendance, all eager to scoop one of the coveted prizes from the world’s largest healthcare awards programme.
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry